Valuation: Clover Corporation Limited

Market Cap 149M 107M 91.77M 85.87M 78.6M 148M 10.25B 1.01B 396M 5.15B 402M 394M 17.03B P/E 2026 *
15.4x
P/E 2027 * 11.2x
Enterprise Value 147M 105M 90.36M 84.55M 77.39M 145M 10.09B 999M 390M 5.07B 396M 387M 16.77B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.23x
Free-Float
76.93%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 11/11/2014
Director of Finance/CFO - 06/05/2021
Chief Operating Officer - 03/02/2011
Director TitleAgeSince
Director/Board Member - 11/11/2014
Chairman - 21/09/2017
Director/Board Member - 01/02/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 107M
-1.52%-0.86%+15.29%+75.41% 12.7B
-5.37%+20.19%-2.20%+399.15% 10.15B
-2.21%-4.05%-21.93%-49.22% 2.42B
+0.91%+3.29%-13.83%-4.64% 1.51B
+0.04%+0.18%+23.82%+78.62% 1.38B
+4.12%+2.60%+37.80%-19.99% 1.33B
-2.49%-5.21%-74.38%-74.18% 1.18B
-1.28%-5.10%-42.74% - 1.05B
-1.00%-3.80%-62.96%-68.13% 962M
Average -0.88%-0.15%-15.68%+42.13% 3.63B
Weighted average by Cap. -2.36%+1.77%-0.39%+152.11%

Financials

2026 *2027 *
Net sales 94M 67.38M 57.72M 54M 49.43M 92.77M 6.45B 638M 249M 3.24B 253M 247M 10.71B 116M 83.22M 71.29M 66.7M 61.06M 115M 7.96B 788M 307M 4B 312M 306M 13.23B
Net income 9.8M 7.02M 6.02M 5.63M 5.15M 9.67M 672M 66.52M 25.94M 338M 26.38M 25.8M 1.12B 13.5M 9.68M 8.29M 7.76M 7.1M 13.32M 926M 91.63M 35.73M 465M 36.34M 35.54M 1.54B
Net Debt -2.3M -1.65M -1.41M -1.32M -1.21M -2.27M -158M -15.61M -6.09M -79.24M -6.19M -6.06M -262M -7.2M -5.16M -4.42M -4.14M -3.79M -7.11M -494M -48.87M -19.06M -248M -19.38M -18.96M -820M
Logo Clover Corporation Limited
Clover Corporation Limited focused on technology, new product development, and commercialization. The principal activities of the Company are the refining and sale of natural oils, the production of encapsulated powders and the research and product development of functional food and infant nutrition ingredients. Its microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formulas, foods, and beverages. Its technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. The Company, through its subsidiary, Nu-Mega Ingredients Pty Limited (Nu-Mega), supplies refined Omega-3 oils and a range of other encapsulated ingredients for use in infant formula, nutraceuticals, pharmaceuticals, and sports nutrition markets. Nu-Mega’s Driphorm range of microencapsulated powders enables the addition of Hi-DHA tuna and/or algal oils to a broad spectrum of products.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9000AUD
Average target price
1.280AUD
Spread / Average Target
+42.22%

Annual profits - Rate of surprise